Browse the latest forensic toxicology articles or search the collection.
-
Two Extraction Conditions Separated THC From Its Carboxy Metabolite
The GC–MS method extracted parent THC first and then changed the remaining phase for THC-COOH recovery. Its performance belonged to a two-stage preparation, not a single universal extraction step. The sequence was part of the assay After internal-standard addition and basic preparation, the workflow used a hexane–ethyl-acetate mixture to recover the parent-drug fraction. The remaining…
-
Matrix Effects and Extraction Losses Were Different Neonatal Assay Findings
The assay measured matrix effects separately from extraction recovery. A suppressed instrument response and loss during sample preparation are different problems, even when both can influence the final cannabinoid signal. The authors used distinct comparisons In meconium, reported matrix-effect values included 78% for THC and 79% for CBD, where 100% represented no matrix effect. Cord…
-
A 72-Hour Autosampler Check Did Not Validate Long-Term Neonatal Specimen Storage
The study checked prepared cannabinoid extracts in a refrigerated autosampler for 72 hours. That experiment did not establish long-term stability of unprocessed meconium or umbilical-cord tissue. What was placed under study conditions The authors evaluated extracted cannabinoids at several concentrations for each matrix. At 4°C in the autosampler for 72 hours, expected concentrations remained within…
-
Low CBD Solid-Phase Recovery Coexisted With Acceptable Meconium Accuracy
The meconium method reported low CBD recovery at one extraction stage alongside acceptable overall accuracy. Extraction recovery and the accuracy of the final reported concentration were different validation outputs. The table separated the metrics For CBD, the neonatal-matrix paper reported average solid-phase-extraction recovery of 27%, method recovery of 94% and average accuracy of 97% in…
-
Single-Point Hair Calibration Still Used Multiple Quality Controls
The GC–MS/MS hair assay used a single-point calibration with separate controls and validated limits. It should not be described either as a full multi-point calibration in every run or as a method with no performance checks. What the analytical protocol specified Quantification used analyte-to-internal-standard area ratios, calibrated at 5 pg/mg for THC and 0.5 pg/mg…
-
A Lower Urine Screen Before Dosing Did Not Erase Earlier Hair Exposure
Before experimental dosing, participants supplied urine until the immunoassay result was below 20 ng/mL. That urinary criterion did not establish that their existing hair contained no cannabinoids from earlier use. The study used a matrix-specific entry sequence Participants initially qualified with a positive urine cannabinoid screen and a documented cannabis-use history. After admission to a…
-
Hair-Test Wash Solutions Were Discarded, Not Quantified
The hair study washed specimens but discarded the wash solutions. Its final hair concentrations therefore were not accompanied by quantitative wash results that could reconstruct the amount removed from the surface. Preparation differed by testing workflow For GC–MS/MS, the protocol used a buffer wash followed by water, methanol and water washes before hair digestion and…
-
Inapplicable Questionnaire Items Reduced Usable Data in the Autism Trial
Some standardized questionnaire items were inapplicable to participants with substantial functional limitations. The resulting invalid scores reduced usable data and statistical power rather than constituting observed lack of improvement. The trial included a broad population Participants ranged from five to twenty-one years old and had varied functional abilities. The authors reported that standardized questionnaires contained…
-
Clinical Liver Observations Were Not Liver-Enzyme Testing in the Autism Trial
The authors observed no clinical evidence of liver or blood-system dysfunction but did not obtain liver-enzyme tests or complete blood counts. Those statements describe different levels of safety observation. What the report actually documented The proof-of-concept trial monitored tolerability of CBD/THC preparations and placebo. It reported common adverse events, including sleepiness and decreased appetite, and…
-
The Autism Cannabinoid Trial Did Not Measure Pharmacokinetic Exposure
The trial did not obtain pharmacokinetic data for the cannabinoid interventions or concomitant medications. A prescribed dose therefore cannot be presented as a measured systemic exposure in these participants. Dose and concentration were separate questions The study compared whole-plant CBD/THC extract, purified CBD plus THC and placebo. Both active products used the same nominal 20:1…
-
Cognitive Testing and Plasma Collection Used Different Post-Dose Times
The Parkinson trial scheduled comprehensive cognitive testing about one and a half hours after the final dose and plasma collection at three hours. Those observations were not simultaneous measurements of concentration and performance. The protocol used distinct windows Cannabinoids and metabolites were measured in plasma at initial and final dose visits, with collection three hours…
-
Many Parkinson Cannabis Outcomes Were Tested Without a Multiplicity Adjustment
The investigators did not plan a multiple-testing adjustment across the many different outcomes. Secondary signals should therefore remain distinct from a confirmatory finding on the primary motor endpoint. The trial specified a primary question The study compared CBD/THC with placebo for change in motor MDS-UPDRS score. It also examined numerous motor, nonmotor, safety and exploratory…
-
The Parkinson Cannabis Trial Required Participants Not to Drive
Participants agreed not to drive while taking the study drug. The Parkinson trial therefore cannot be cited as a demonstration that its CBD/THC regimen preserved real-world driving ability. The restriction shaped participation The trial tested an oral CBD/THC solution against placebo in 61 randomized participants. Its eligibility and procedures included a no-driving agreement. The recruitment…
-
Cannabis Odor Changed How the Parkinson Trial Protected Blinding
The Parkinson trial used opaque packaging, odor-control procedures and a parallel design to reduce recognition of cannabis treatment. These safeguards addressed a concrete masking problem without proving that every participant remained unaware. The products were not perfectly matched Despite added flavoring, the active CBD/THC solution and placebo differed slightly in appearance and odor. The investigators…
-
Unreported Outcomes in the Cannabis-Cigarette Trial Were Not Zero Events
The cannabis-cigarette study in the 2018 review did not report several important outcomes. Missing reporting should not be translated into zero adverse events, no withdrawals or a demonstrated remission result. An abstract supplied limited information The review included a 32-participant trial of smoked cannabis versus placebo cigarettes, available as a conference abstract. It reported disease-activity…
-
The Colitis Cannabis Review Assigned Certainty to Individual Outcomes
The review did not assign one certainty label to every cannabinoid finding. Remission, inflammatory markers and adverse-event outcomes had separate assessments based on the evidence supporting each one. GRADE followed the endpoint In the capsule comparison, the 2018 review rated remission and clinical-response evidence low certainty. It rated the reported C-reactive-protein and quality-of-life comparisons moderate…
-
Zero Serious Events in a Small Cannabinoid Arm Did Not Establish Protection
No serious adverse events occurred in the capsule trial’s cannabinoid group. With only 29 participants and a wide comparative interval, that observation did not demonstrate protection against serious harm. The review separated event severity The historical Cochrane synthesis reported no serious events in the cannabinoid arm and three among 31 placebo participants. The estimated risk…
-
More Colitis Participants Stopped Cannabinoid Treatment, but the Estimate Was Uncertain
Withdrawal because of an adverse event was more frequent in the cannabinoid arm of the capsule trial, but the comparative estimate was imprecise. The reasons for withdrawal also differed between groups. The counts and reasons both mattered The 2018 review reported adverse-event withdrawals in ten of 29 cannabinoid participants and five of 31 placebo participants.…
-
The Colitis CBD Remission Estimate Was Too Imprecise to Establish Equivalence
The 2018 Cochrane review reported similar remission percentages with CBD-containing capsules and placebo, but a wide confidence interval. Similar observed percentages did not establish that the treatments were equivalent. What the review reported Seven of 29 participants receiving the cannabinoid preparation achieved remission at ten weeks, compared with eight of 31 receiving placebo. The risk…
-
Oil and Cannabis-Tea Comparisons Did Not Point in One Uniform Direction
The oral-cannabis review described differing results when oil and decoction preparations were compared. One pilot’s findings came from a single person, limiting any claim that one preparation invariably produces higher exposure. The reviewed comparisons differed One published comparison reported greater availability of CBDA after decoction and greater availability of THC and its metabolites after oil.…